Company / Capital Expenditures
Pacira BioSciences, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$15.3M
FY2025
5-year range
$10.2M / $30.1M
FY2021-FY2025
Trend
+44.2%
vs FY2024
Sector context
#47 of 194
Health Care
What the data says
Pacira BioSciences, Inc.'s capital expenditures of $15M is higher than 76% of companies in the Health Care sector (FY2025). Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $15M.
Based on SEC 10-K filings.
$15M in FY2025 with a 5-year CAGR of +1.1%. Top quartile in the Health Care sector.
Remained stable around $15M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -20.1%
- 5-Year CAGR
- +1.1%
- 10-Year CAGR
- -
Sector benchmark
-87.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.1%, indicating consistent growth.
- In FY2025, capital expenditures increased 44.2% year-over-year.
- Ranks #47 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2017.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.3M | +44.2% |
| FY2024 | $10.6M | -29.8% |
| FY2023 | $15.2M | -49.6% |
| FY2022 | $30.1M | +196.1% |
| FY2021 | $10.2M | -30.0% |
| FY2020 | $14.5M | -24.7% |
| FY2019 | $19.3M | -22.0% |
| FY2018 | $24.7M | -38.7% |
| FY2017 | $40.3M | +63.1% |
| FY2016 | $24.7M | -38.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026